

Gordon W Rewcastle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1956404/publications.pdf>

Version: 2024-02-01

30
papers

1,966
citations

535685

17
h-index

536525

29
g-index

31
all docs

31
docs citations

31
times ranked

2624
citing authors

#	ARTICLE	IF	CITATIONS
1	Synthesis and Evaluation of Imidazo[1,2-a]pyridine Analogues of the ZSTK474 Class of Phosphatidylinositol 3-Kinase Inhibitors. <i>Chemistry - an Asian Journal</i> , 2019, 14, 1249-1261.	1.7	9
2	Synthesis and biological evaluation of solubilized sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 1529-1545.	1.4	12
3	Novel pyrazolo[1,5-a]pyridines with improved aqueous solubility as p110 α -selective PI3 kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 187-190.	1.0	9
4	Combining properties of different classes of PI3K α inhibitors to understand the molecular features that confer selectivity. <i>Biochemical Journal</i> , 2017, 474, 2261-2276.	1.7	6
5	Synthesis and biological evaluation of sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 5859-5874.	1.4	14
6	Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3K α , in comparison to established pan PI3K inhibitors. <i>Oncotarget</i> , 2017, 8, 47725-47740.	0.8	11
7	Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth. <i>Frontiers in Oncology</i> , 2015, 5, 135.	1.3	52
8	Exploring the isoform selectivity of TGX-221 related pyrido[1,2-a]pyrimidinone-based Class IA PI 3-kinase inhibitors: Synthesis, biological evaluation and molecular modelling. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 3796-3808.	1.4	9
9	Inhibitors of the Phosphatidylinositol 3-Kinase Pathway. , 2014, , 449-478.		3
10	Novel pyrazolo[1,5-a]pyridines as PI3K inhibitors: variation of the central linker group. <i>MedChemComm</i> , 2014, 5, 41-46.	3.5	12
11	Abstract 1644: Design and discovery of PWT33597 (VDC-597), a dual inhibitor of PI3-kinase alpha and mTOR. <i>Cancer Research</i> , 2014, 74, 1644-1644.	0.4	2
12	Synthesis and biological evaluation of novel phosphatidylinositol 3-kinase inhibitors: Solubilized 4-substituted benzimidazole analogs of 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474). <i>European Journal of Medicinal Chemistry</i> , 2013, 64, 137-147.	2.6	17
13	Discovery of pyrazolo[1,5-a]pyridines as p110 α -selective PI3 kinase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 69-85.	1.4	30
14	Novel pyrazolo[1,5-a]pyridines as p110 α -selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 58-68.	1.4	34
15	A drug targeting only p110 α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. <i>Biochemical Journal</i> , 2011, 438, 53-62.	1.7	137
16	Synthesis and Biological Evaluation of Novel Analogues of the Pan Class I Phosphatidylinositol 3-Kinase (PI3K) Inhibitor 2-(Difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474). <i>Journal of Medicinal Chemistry</i> , 2011, 54, 7105-7126.	2.9	97
17	Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. <i>Biochemical Journal</i> , 2007, 404, 449-458.	1.7	188
18	Identification of a Unique Co-operative Phosphoinositide 3-Kinase Signaling Mechanism Regulating Integrin α IIb β 3 Adhesive Function in Platelets. <i>Journal of Biological Chemistry</i> , 2007, 282, 28648-28658.	1.6	78

#	ARTICLE	IF	CITATIONS
19	Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110 α inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 7677-7687.	1.4	51
20	An improved synthesis of isonitrosoacetanilides. <i>Tetrahedron Letters</i> , 2005, 46, 8719-8721.	0.7	15
21	Becatecarin (Helsinn Healthcare). <i>IDrugs: the Investigational Drugs Journal</i> , 2005, 8, 838-47.	0.7	1
22	Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 1380-1397.	2.9	261
23	Bis(phenazine-1-carboxamides): Structure-Activity Relationships for a New Class of Dual Topoisomerase I/II-Directed Anticancer Drugs. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 1350-1358.	2.9	95
24	Tyrosine Kinase Inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(Phenylamino)pyrido[d]pyrimidine Acrylamides as Irreversible Inhibitors of the ATP Binding Site of the Epidermal Growth Factor Receptor. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 1803-1815.	2.9	173
25	Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 323-330.	1.1	40
26	Tyrosine Kinase Inhibitors. 14. Structure-Activity Relationships for Methyl-amino-Substituted Derivatives of 4-[(3-Bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a Potent and Specific Inhibitor of the Tyrosine Kinase Activity of Receptors for the EGF Family of Growth Factors. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 742-751.	2.9	103
27	Tyrosine Kinase Inhibitors. 9. Synthesis and Evaluation of Fused Tricyclic Quinazoline Analogues as ATP Site Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 918-928.	2.9	162
28	Tyrosine Kinase Inhibitors. 8. An Unusually Steep Structure-Activity Relationship for Analogues of 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a Potent Inhibitor of the Epidermal Growth Factor Receptor. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 267-276.	2.9	304
29	STRUCTURE-ACTIVITY RELATIONSHIPS FOR 4-ANILINOQUINAZOLINES AS POTENT INHIBITORS AT THE ATP BINDING SITE OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN VITRO. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1996, 23, 424-427.	0.9	30
30	The Synthesis of 9-Oxo-9, 10-Dihydroacridine-4-carboxylic Acids via the Jourdan-Ullmann Reaction of Anthranilic Acids and Methyl 2-Iodobenzoates. <i>Synthetic Communications</i> , 1987, 17, 309-317.	1.1	11